This inventor holds 1 USPTO granted patent. Top assignee: H. Lundbeck A/s. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Antonio Cincotti: Innovator in Pharmaceutical Chemistry
Introduction
Antonio Cincotti is a notable inventor based in Edinburgh, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds. His work has led to the creation of a patent that showcases his innovative approach to drug design.
Latest Patents
Antonio Cincotti holds a patent for crystalline forms of a MAGL inhibitor. The patent describes new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof. This invention represents a significant advancement in the search for effective treatments.
Career Highlights
Cincotti is currently employed at H. Lundbeck A/S, a leading global pharmaceutical company. His role involves research and development, where he applies his expertise to create innovative solutions in the pharmaceutical industry. His dedication to advancing medical science is evident in his work and contributions.
Collaborations
Throughout his career, Antonio has collaborated with esteemed colleagues, including Thomas Vetter and Martin Juhl. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the innovation process.
Conclusion
Antonio Cincotti is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable advancements in drug development. His patent for a MAGL inhibitor exemplifies his commitment to innovation and improving healthcare solutions.